Navigation Links
New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia

Findings indicate early non-responders unlikely to subsequently respond, have substantially more treatment costs, and may benefit from earlier change in treatment strategy

COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/ -- New data presented at the 2007 International Congress on Schizophrenia Research (ICOSR) suggest that antipsychotic drug response be assessed earlier than is presently thought, and challenge the current schizophrenia treatment paradigm for when to evaluate if an antipsychotic medication is working effectively.

The findings show that early non-response to antipsychotic medication, as early as two weeks into treatment, appears to strongly predict subsequent lack of response in patients with schizophrenia. Compared to "early responders" - patients who responded to their antipsychotic medication after two weeks of treatment - the "early non-responders" were less likely to achieve subsequent symptom remission, viewed medication adherence as less beneficial, had a lower level of functioning, and incurred twice as many total healthcare costs. The studies were conducted and funded by Eli Lilly and Company.

Early non-response may be a powerful marker to not only predict prognosis in schizophrenia, but also tailor appropriate treatment to the patient's immediate needs. These data support the need for clinicians' early evaluation of patients' treatment response, and the possible need for a change in the medication to potentially help minimize prolonging exposure to sub-optimal or ineffective treatment.

Current schizophrenia treatment guidelines recommend an initial trial of four to six weeks to determine if a patient will respond to an antipsychotic medication(i). However, these new data suggest this may be too long. Without early and effective treatment, patients with schizophrenia may experience devastating and costly events, such as hospitalization(ii), incarceratio
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
4. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
5. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
6. Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data
7. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
8. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
9. Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron
10. Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability
11. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
Post Your Comments:
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2
... April 16, 2007 /PRNewswire/ -- Sirion Therapeutics,Inc., ... has received orphan drug designation from the ... therapy,ganciclovir, for the treatment of acute herpetic ... Thea in Europe under,the brand name of ...
... at 2007 APA Meeting Also Showed No,Significant Impact ... 21, 2007 /PRNewswire-FirstCall/ --,Findings from two separate pooled ... on anxious symptoms and the,other on painful symptoms ... as a separate pooled analysis that examined the,effect ...
Cached Medicine Technology:Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 3Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 4Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 5Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 6
(Date:12/26/2014)... India Network Foundation, a non-profit US based sponsor ... a new version of “ EasySelect ”, a software ... for their visiting parents. The technology tool is designed ... when choosing an insurance plan by showing the benefits ... clicks. Many elderly Asian Indian parents often find it ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Option for the Treatment of ED-, INDIANAPOLIS, Jan. ... announced today that the U.S. Food and Drug Administration,(FDA) ... mg and,5 mg), an oral medication taken once per ... daily use is taken daily, men can attempt sexual,activity ...
... to Board of Directors, CINCINNATI, Jan. 8, ... PG ) today announced the appointment of Patricia ... Archer Daniels Midland,Corporation (NYSE: ADM ), to ... http://www.newscom.com/cgi-bin/prnh/20080108/CLTU115-a ), (Photo: http://www.newscom.com/cgi-bin/prnh/20080108/CLTU115-b ...
... Texas, Jan. 8 In 2006, 66% of Americans ... come from working in,seated sedentary jobs? Or do we ... or obese? No one knows for sure, but Texas ... to reverse this trend. Recently,Neutral Posture introduced the Ntune(TM) ...
... Big Rewards, CINCINNATI, Jan. 8 As part of ... be holding its Community Event,in all 2,435 Wal-Mart Supercenters across ... to teach, encourage and inspire women to take,control of their ... big rewards for their overall health and well-being., The ...
... 8 Bristol-Myers Squibb Company,(NYSE: BMY ... private equity firm,announced today that Avista has ... a business unit of Bristol-Myers Squibb. Bristol-,Myers ... of medical imaging,products for nuclear and ultrasound ...
... For twenty years, The Leukemia &,Lymphoma Society ... changed,lives, helped individuals achieve personal goals and most ... research., (See video from The Leukemia & ... diverse individuals, "Team In Training" helps,individuals prepare for ...
Cached Medicine News:Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:Procter & Gamble Announces Appointment of Director 2Health News:Office Furniture That Helps Fight Fat! 2Health News:Speaking of Women's Health 'Community Event' Returns to All Wal-Mart Supercenters Nationwide January 12th 2Health News:Speaking of Women's Health 'Community Event' Returns to All Wal-Mart Supercenters Nationwide January 12th 3Health News:Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging 2
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Liquichek™ Homocysteine Control is a liquid control for monitoring homocysteine test procedures. This product can be used or methods such as HPLC and automated immunoassay procedures....
Lyphochek Hemostasis Control is a multi-analyte control to help monitor coagulation factor assays and selected thrombosis risk assays. Assayed values are available for most major instrumentation....
... Qualitative Urine Toxicology Control is a liquid ... urine drug screen panels, including Point of ... kits like Bio-Rad TOX/See, Biosite Triage and ... results (+/) for popular kits and recovery ...
Medicine Products: